This therapy showed promising anti-tumor effect, but also relevant side effects: e.g. a recently published systematic review and meta-analysis reported a pooled rate of any-grade xerostomia in 84% of patients receiving [225Ac]Ac-PSMA monotherapy and a therapy discontinuation due to xerostomia in 5% of cases 23. The gene discussed is FOLH1; the disease is xerostomia.